首页> 外文期刊>Mutagenesis >Low-dose radiation from 18F-FDG PET does not increase cancer frequency or shorten latency but reduces kidney disease in cancer-prone Trp53+/- mice.
【24h】

Low-dose radiation from 18F-FDG PET does not increase cancer frequency or shorten latency but reduces kidney disease in cancer-prone Trp53+/- mice.

机译:18F-FDG PET的低剂量放射不会增加癌症发生频率或缩短潜伏期,但可以减少易患癌症的Trp53 +/-小鼠的肾脏疾病。

获取原文
获取原文并翻译 | 示例
           

摘要

There is considerable interest in the health effects associated with low-level radiation exposure from medical imaging procedures. Concerns in the medical community that increased radiation exposure from imaging procedures may increase cancer risk among patients are confounded by research showing that low-dose radiation exposure can extend lifespan by increasing the latency period of some types of cancer. The most commonly used radiopharmaceutical for positron emission tomography (PET) scans is 2-[(18)F] fluoro-2-deoxy-d-glucose ((18)F-FDG), which exposes tissue to a low-dose, mixed radiation quality: 634 keV β+ and 511 keV γ-rays. The goal of this research was to investigate how modification of cancer risk associated with exposure to low-dose ionising radiation in cancer-prone Trp53+/- mice is influenced by radiation quality from PET. At 7-8 weeks of age, Trp53+/- female mice were exposed to one of five treatments: 0 Gy, 10 mGy γ-rays, 10 mGy (18)F-FDG, 4 Gy γ-rays, 10 mGy (18)F-FDG + 4 Gy γ-rays (n > 185 per group). The large 4-Gy radiation dose significantly reduced the lifespan by shortening the latency period of cancer and significantly increasing the number of mice with malignancies, compared with unirradiated controls. The 10 mGy γ-rays and 10 mGy PET doses did not significantly modify the frequency or latency period of cancer relative to unirradiated mice. Similarly, the PET scan administered prior to a large 4-Gy dose did not significantly modify the latency or frequency of cancer relative to mice receiving a dose of only 4 Gy. The relative biological effectiveness of radiation quality from (18)F-FDG, with respect to malignancy, is approximately 1. However; when non-cancer endpoints were studied, it was found that the 10-mGy PET group had a significant reduction in kidney lesions (P < 0.021), indicating that a higher absorbed dose (20 ± 0.13 mGy), relative to the whole-body average, which occurs in specific tissues, may not be detrimental.
机译:人们对与医学成像程序进行低剂量辐射相关的健康影响非常感兴趣。研究表明,低剂量放射线可以延长某些类型癌症的潜伏期,从而延长寿命,这使医学界担心成像程序增加的放射线暴露可能会增加患者患癌症的风险。用于正电子发射断层扫描(PET)扫描的最常用的放射性药物是2-[((18)F]氟-2-脱氧-d-葡萄糖((18)F-FDG),它使组织暴露于低剂量,混合的辐射质量:634 keVβ+和511 keVγ射线。这项研究的目的是研究在易患癌症的Trp53 +/-小鼠中,与暴露于低剂量电离辐射相关的癌症风险的改变如何受到PET辐射质量的影响。在7-8周龄时,将Trp53 +/-雌性小鼠接受五种治疗之一:0 Gy,10 mGyγ射线,10 mGy(18)F-FDG,4 Gyγ射线,10 mGy(18) F-FDG + 4 Gyγ射线(每组n> 185)。与未经辐照的对照组相比,较大的4-Gy辐照剂量可通过缩短癌症的潜伏期并显着增加患有恶性肿瘤的小鼠数量来显着缩短寿命。相对于未辐照的小鼠,10 mGyγ射线和10 mGy PET剂量并未显着改变癌症的发生频率或潜伏期。类似地,相对于仅接受4 Gy剂量的小鼠,在大剂量4-Gy之前进行的PET扫描不会显着改变癌症的潜伏期或频率。 (18)F-FDG辐射质量相对于恶性的相对生物学有效性约为1。当研究非癌症终点时,发现10-mGy PET组的肾脏病变显着减少(P <0.021),表明相对于全身而言,更高的吸收剂量(20±0.13 mGy)发生在特定组织中的平均值可能不会有害。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号